Globus Medical (NYSE:GMED – Get Free Report) had its target price dropped by investment analysts at Truist Financial from $90.00 to $82.00 in a research note issued to investors on Tuesday,Benzinga ...

Globus Medical (NYSE:GMED – Get Free Report)‘s stock had its “hold” rating restated by equities researchers at Needham & ...

According to Benzinga Pro, Globus Medical's peer group average for short interest as a percentage of float is 4.18%, which means the company has less short interest than most of its peers. Did you ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...

Learn more about whether Globus Medical, Inc. or QuidelOrtho Corporation is a better investment based on AAII's A+ Investor ...

Globus Medical, Inc. reported $657,293 million in sales and $60,275 million in operating profit for the quarter ending ...

Medtech company Globus Medical has expanded its spine portfolio by launching its Cohere anterior lumbar interbody fusion spacer and Modulus ALIF blades. The Cohere space is the first porous ...